Karyopharm's innovative therapy Xpovio (selinexor) Phase 2b clinical trial yields positive results
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Karyopharm Therapeuticscompany(http://announced positive results from theof its innovative clinical(http:// for the treatment of recurrent/incurable multiple myelomastudy was published in the New England Journal of Medicine (NEJM)Xpovio
Xpovio is a "first-in-class" oral protodosis selective nuclear output inhibitor that binds to the nucleoid protein XPO1 and inhibits its function, thus blocking the nuclear output of tumor suppressors, growth-regulating proteins, and anti-inflammatory proteins, causing it to accumulate in the nucleus, restart or enhance its tumor inhibition functionJuly 2019, Xpovio received accelerated approval from the u.SFDA(http://This innovative therapy can be combined with dexamethasone to treat patients with recurrent/incurable multiple myelomaPhase 2b clinical trials recruited 122 patients with stage 3 recurrent/refractory multiple myeloma who received an average of seven treatments in the previous period and developed rapidlypatients received Xpovio and dexamethasone combined administration, 39% (48) of the condition stabilized, with a total remission rate of 26%, with a median total survival of 8.6 months
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
